RELMADA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.53 USD | -7.11% |
|
-4.08% | -14.73% |
| May. 08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Relmada Therapeu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Calendar
2024-05-24
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.53
USD
Average target price
13.5
USD
Spread / Average Target
+282.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.73% | 107M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Transcript : Relmada Therapeutics, Inc., Q4 2021 Earnings Call, Mar 23, 2022
